<SEC-DOCUMENT>0001171843-23-003914.txt : 20230614
<SEC-HEADER>0001171843-23-003914.hdr.sgml : 20230614
<ACCEPTANCE-DATETIME>20230614070251
ACCESSION NUMBER:		0001171843-23-003914
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230613
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230614
DATE AS OF CHANGE:		20230614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		231012985

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_061423.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:BCRX="http://biocryst.com/20230613">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_BCRX_biocryst.com_20230613 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20230613_20230613 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000882796 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:EntityCentralIndexKey">0000882796</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="bcrx-20230613.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-06-13to2023-06-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-13</xbrli:startDate>
        <xbrli:endDate>2023-06-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>SECURITIES AND
EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Washington, D.C.
20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 16pt">FORM <span id="xdx_906_edei--DocumentType_c20230613__20230613_z3IvJQnLFwFj"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:DocumentType">8-K</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_902_edei--DocumentPeriodEndDate_c20230613__20230613_zprQw29IQRo5"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 13, 2023</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityRegistrantName_c20230613__20230613_zhVk1iSpXmy4"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:EntityRegistrantName">BioCryst Pharmaceuticals, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20230613__20230613_zVbgkfzM1uAa"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20230613__20230613_zgpwsoTNbRa2"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:EntityFileNumber">000-23186</ix:nonNumeric></span></b></span></td>
    <td style="width: 33%; padding-left: 16.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20230613__20230613_zBY0pRK8pfVe"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:EntityTaxIdentificationNumber">62-1413174</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></td>
    <td style="padding-left: 17.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of Incorporation)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File Number)</span></td>
    <td style="padding-left: 16.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 100%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20230613__20230613_zX7lPhng8P25"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:EntityAddressAddressLine1">4505 Emperor Blvd.</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20230613__20230613_zE6T8K335wA8"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityAddressCityOrTown_c20230613__20230613_zy2nufTSlF"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:EntityAddressCityOrTown">Durham</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20230613__20230613_zmAnUJ9mqjH9"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">North Carolina</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20230613__20230613_zNuSQay2RWE"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:EntityAddressPostalZipCode">27703</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">(Address of Principal Executive Offices) (Zip Code)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--CityAreaCode_c20230613__20230613_zgZVGbxLMlye"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:CityAreaCode">(919)</ix:nonNumeric></span> <span id="xdx_905_edei--LocalPhoneNumber_c20230613__20230613_z76cqRJWIPq1"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:LocalPhoneNumber">859-1302</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif">(Registrant&#8217;s telephone number, including area code)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">________________________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report.)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 8.5pt"></td><td style="width: 24.5pt"><span id="xdx_901_edei--WrittenCommunications_c20230613__20230613_zuARzzDjThle"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td><td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 8.5pt"></td><td style="width: 24.5pt"><span id="xdx_90C_edei--SolicitingMaterial_c20230613__20230613_z0cskuQJJwec"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td><td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 8.5pt"></td><td style="width: 24.5pt"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20230613__20230613_zGM0Hpm1bfs7"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td><td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 8.5pt"></td><td style="width: 24.5pt"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20230613__20230613_zbqJcKZdZKHl"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td><td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border: Black 1pt solid; width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td>
    <td style="border-top: Black 1pt solid; width: 35%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: Black 1pt solid; width: 32%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--Security12bTitle_c20230613__20230613_zuh83GHcgg49"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--TradingSymbol_c20230613__20230613_zPaDi1XVkDu2"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" name="dei:TradingSymbol">BCRX</ix:nonNumeric></span></b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--SecurityExchangeName_c20230613__20230613_zdNkCWnUhVx6"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 19pt 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act
of 1934 (17 CFR &#167;240.12b-2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 19pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20230613__20230613_z27GBOXKUEFd"><ix:nonNumeric contextRef="From2023-06-13to2023-06-13" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 13, 2023, at the 2023 Annual Meeting of
Stockholders (the &#8220;Annual Meeting&#8221;) of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;), the Company&#8217;s stockholders
approved, by the affirmative vote of a majority of the shares of the Company&#8217;s common stock represented in person or by proxy at
the Annual Meeting and voting on the proposal, a proposal to amend and restate the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan
(such plan, as amended and restated, the &#8220;Stock Incentive Plan&#8221;), increasing the number of shares available for issuance under
the Stock Incentive Plan by 7,000,000 shares (the &#8220;Incentive Plan Proposal&#8221;). A detailed description of the Stock Incentive
Plan is included in the Company&#8217;s Definitive Proxy Statement for the Annual Meeting. The description of the Stock Incentive Plan
in this report does not purport to be complete and is qualified in its entirety by reference to the full text of the Stock Incentive Plan,
a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5.07. Submission of Matters to a Vote
of Security Holders.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Annual Meeting was held on June 13, 2023 for
the purpose of (1) electing four directors to serve for a term ending at the Company&#8217;s 2026 annual meeting of stockholders and until
a successor is duly elected and qualified; (2) ratifying the selection of Ernst &amp; Young LLP as the Company&#8217;s independent registered
public accountants for 2023; (3) holding an advisory vote approving the Company&#8217;s executive compensation; (4) holding an advisory
vote on the frequency of future advisory votes on the Company&#8217;s executive compensation; and (5) approving the Incentive Plan Proposal
described in Item 5.02 above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The nominees for director were elected by the
following votes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: top">
    <td style="width: 52%; text-align: justify">&#160;</td>
    <td style="width: 3%; text-align: justify">&#160;</td>
    <td style="width: 21%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">FOR</span></span></td>
    <td style="width: 4%; text-align: justify">&#160;</td>
    <td style="width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">WITHHELD</span></span></td></tr>
  <tr>
    <td style="vertical-align: top; background-color: #CCECFF; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: #CCECFF">George B. Abercrombie</span></td>
    <td style="vertical-align: top; background-color: #CCEEFF; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; background-color: #CCEEFF; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,339,248</span></td>
    <td style="vertical-align: bottom; background-color: #CCEEFF; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; background-color: #CCEEFF; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,886,055</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">Theresa M. Heggie</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109,979,956</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,245,347</span></td></tr>
  <tr style="background-color: #CCECFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: #CCECFF">Amy E. McKee, M.D.</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,962,885</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,262,418</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">Jon P. Stonehouse</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,813,870</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,411,433</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, there were 29,924,456 broker non-votes
for each director.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed ratification of the selection of
Ernst &amp; Young LLP as the Company&#8217;s independent registered public accountants for 2023 was approved by the following votes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 66%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">FOR</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 34%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">147,314,382</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">AGAINST</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,420,578</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABSTAIN</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">414,799</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposed advisory resolution regarding executive
compensation was approved by the following votes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 66%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">FOR</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 34%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,956,369</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">AGAINST</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,424,056</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABSTAIN</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">844,878</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">BROKER NON-VOTES</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,924,456</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proposal relating to the advisory vote on
the frequency of future advisory votes on the Company&#8217;s executive compensation was voted on as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 66%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ONE YEAR</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 34%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,872,561</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">TWO YEARS</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">490,032</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">THREE YEARS</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,607,253</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABSTAIN</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,255,457</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In light of these voting results, the Company
plans to hold future advisory votes approving executive compensation annually until the next required vote on the frequency of such advisory
votes, or until the Board of Directors of the Company otherwise determines that a different frequency is in the best interests of the
Company and its stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Incentive Plan Proposal was approved by the
following votes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 66%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">FOR</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 34%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80,642,552</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">AGAINST</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,582,731</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ABSTAIN</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,000,020</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">BROKER NON-VOTES</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,924,456</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no other business voted upon at the
Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01. Financial Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; white-space: nowrap; font-weight: bold; width: 10%">Exhibit No.</td><td style="font-weight: bold; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; width: 88%">Description</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap">&#160;</td><td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><a href="exh_101.htm">10.1</a></td><td>&#160;</td>
    <td style="text-align: left"><a href="exh_101.htm">BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 24, 2023)</a></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; text-indent: -1in; padding-left: 1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">104</td><td>&#160;</td>
    <td style="text-align: left">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Date:&#160;&#160;June 14, 2023</span></td>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>BioCryst Pharmaceuticals, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 33%; text-align: justify">&#160;</td>
    <td style="width: 18%; text-align: justify">&#160;</td>
    <td style="width: 4%"> By:</td>
    <td style="border-bottom: Black 1pt solid; width: 45%"> /s/ Alane Barnes</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Alane Barnes</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Chief Legal Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="margin: 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fm1a/KGPFhWxihQRX6NdJdhmyyateiRvaWwRl4VlmflmhBiIFS11iQyneZ7BAau6VA4hxysymgt6R7reJOBvjjdtHSvjuvcHpuQZ9Mx4KGdnL3TWVlssEggnIxmPohhklMRT2G9F8NVTMlddoHFalaBMAXummjU6xa8+4aCeZKh6dVVHZKvJJCCHYS+/IQplBDtq1YP4biHLUhEMugnEiqmpvzWNdVTBosTKd9ke/W/wAR2SSVI= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exh_101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BIOCRYST PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STOCK INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(AS AMENDED AND RESTATED AS OF APRIL 24, 2023)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
One</B></FONT><B><BR>
<U>GENERAL PROVISIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
PURPOSES OF THE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
This Stock Incentive Plan (the &ldquo;Plan&rdquo;), formerly the &ldquo;BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan,&rdquo;
is intended to promote the interests of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), by providing
a method whereby (i) employees (including officers and directors) of the Company (or its parent or subsidiary corporations), (ii) non-employee
members of the board of directors of the Company (the &ldquo;Board&rdquo;) (or of any parent or subsidiary corporations) and (iii) consultants
and other independent contractors who provide valuable services to the Company (or any parent or subsidiary corporations) may be offered
the opportunity to acquire a proprietary interest, or otherwise increase their proprietary interest, in the Company as an incentive for
them to remain in the service of the Company (or any parent or subsidiary corporations).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For purposes of the Plan, the following provisions shall be applicable in determining the parent and subsidiary corporations of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
corporation (other than the Company) in an unbroken chain of corporations ending with the Company shall be considered to be a <B>parent
</B>corporation of the Company, provided each such corporation in the unbroken chain (other than the Company) owns, at the time of the
determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other
corporations in such chain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
corporation (other than the Company) in an unbroken chain of corporations beginning with the Company shall be considered to be a <B>subsidiary</B>
of the Company, provided each such corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination,
stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations
in such chain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Plan, as amended and restated, was approved and adopted by the Board, effective on April 24, 2023, in order to increase by 7,000,000
the number of shares of the Company&rsquo;s common stock, par value $0.01 per share (the &ldquo;Common Stock&rdquo;), available for issuance
under the Plan, subject to approval by the Company&rsquo;s stockholders at the Company&rsquo;s Annual Meeting of Stockholders on June
13, 2023, and to make certain other changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>II.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
STRUCTURE OF THE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Plan shall be divided into three separate equity programs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Discretionary Option Grant Program specified in Article Two, pursuant to which eligible persons may, at the discretion of the Plan Administrator,
be granted options to purchase shares of Common Stock,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Stock Issuance Program specified in Article Three, pursuant to which eligible persons may, at the discretion of the Plan Administrator,
be issued shares of Common Stock directly or through the issuance of restricted stock units (&ldquo;RSUs&rdquo;) that provide for the
issuance of shares of Common Stock if the applicable vesting criteria are satisfied, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
the Director Grant Program specified in Article Four, pursuant to which non-employee members of the Board may receive grants of awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Unless the context clearly indicates otherwise, the provisions of Articles One and Five of the Plan shall apply to all equity programs
under the Plan and shall accordingly govern the interests of all individuals under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>III.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ADMINISTRATION OF THE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Plan shall be administered by the Committee who shall be the Compensation Committee of the Board or, in the absence of a Compensation
Committee, a properly constituted committee or the Board itself (the administrator is referred to herein as the &ldquo;Committee&rdquo;
or the &ldquo;Plan Administrator&rdquo;). Any power of the Committee may also be exercised by the Board, except to the extent that the
grant or exercise of such authority would cause any award or transaction to become subject to (or lose an exemption under) the short-swing
profit recovery provisions of Section 16 of the Securities Exchange Act of 1934, as amended (the &ldquo;1934 Act&rdquo;). To the extent
that any permitted action taken by the Board conflicts with action taken by the Committee, the Board action shall control. The Committee
may by resolution authorize one or more officers of the Company to perform any or all things that the Committee is authorized and empowered
to do or perform under the Plan, and for all purposes under this Plan, such officer or officers shall be treated as the Committee; provided,
however, that the resolution so authorizing such officer or officers shall specify the total number of awards (if any) such officer or
officers may award pursuant to such delegated authority, and any such award shall be subject to the form of award agreement theretofore
approved by the Compensation Committee. No such officer shall designate himself or herself as a recipient of any awards granted under
authority delegated to such officer. In addition, the Compensation Committee may delegate any or all aspects of the day-to-day administration
of the Plan to one or more officers or employees of the Company or any subsidiary or affiliate, and/or to one or more agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Subject to the express provisions of this Plan, the Committee shall be authorized and empowered to do all things that it determines to
be necessary or appropriate in connection with the administration of this Plan, including, without limitation: (i) to prescribe, amend
and rescind rules and regulations relating to this Plan and to define terms not otherwise defined herein; (ii) to determine which persons
are grantees, to which of such grantees, if any, awards shall be granted hereunder and the timing of any such awards; (iii) to grant awards
to grantees and determine the terms and conditions thereof, including the number of shares of Common Stock subject to awards and the exercise
or purchase price of such shares and the circumstances under which awards become exercisable or vested or are forfeited or expire, which
terms may but need not be conditioned upon the passage of time, continued employment, the satisfaction of performance criteria, the occurrence
of certain events (including events which constitute a Change in Control to the extent permitted hereunder), or other factors; (iv) to
establish and verify the extent of satisfaction of any performance goals or other conditions applicable to the grant, issuance, exercisability,
vesting and/or ability to retain any award; (v) to prescribe and amend the terms of the agreements or other documents evidencing awards
made under this Plan (which need not be identical) and the terms of or form of any document or notice required to be delivered to the
Company by grantees under this Plan; (vi) to determine the extent to which adjustments are required pursuant to Article One; (vii) to
interpret and construe this Plan, any rules and regulations under this Plan and the terms and conditions of any award granted hereunder,
and to make exceptions to any such provisions for the benefit of the Company; (viii) to approve corrections in the documentation or administration
of any award; and (ix) to make all other determinations deemed necessary or advisable for the administration of this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All
decisions, determinations and interpretations by the Committee regarding the Plan, any rules and regulations under the Plan and the terms
and conditions of or operation of any award granted hereunder, shall be final and binding on all grantees, beneficiaries, heirs, assigns
or other persons holding or claiming rights under the Plan or any award. The Committee shall consider such factors as it deems relevant,
in its sole and absolute discretion, to making such decisions, determinations and interpretations including, without limitation, the recommendations
or advice of any officer or other employee of the Company and such attorneys, consultants and accountants as it may select.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The
Committee may delegate all or a portion of their duties hereunder to one or more individuals or committees. Any reference to the Committee
or the Plan Administrator shall refer to such individual(s) or committee(s) to the extent of such delegation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IV.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ELIGIBILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The persons eligible to participate in the Discretionary Option Grant and Stock Issuance Programs shall be limited to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;officers
and other employees of the Company (or its parent or subsidiary corporations);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;individuals
who are consultants or independent advisors and who provide valuable services to the Company (or its parent or subsidiary corporations);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;non-employee
members of the Board (or of the board of directors of parent or subsidiary corporations), subject to the limits set forth in Section II.A.
of Article Four.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Only Board members who are not employees of the Company (or any parent or subsidiary) shall be eligible to receive grants pursuant to
the Director Grant Program specified in Article Four.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Plan Administrator shall, within the scope of its administrative jurisdiction under the Plan, have full power and authority to determine
(i) whether to grant options in accordance with the Discretionary Option Grant Program or to effect stock issuances in accordance with
the Stock Issuance Program, (ii) which eligible persons are to receive option grants under the Discretionary Option Grant Program, the
time or times when such option grants are to be made, the number of shares to be covered by each such grant, the status of the granted
option as either an incentive stock option (&ldquo;Incentive Option&rdquo;) which satisfies the requirements of Section 422 of the Internal
Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;) or a non-statutory option not intended to meet such requirements, the time or
times when each such option is to become exercisable, the vesting schedule (if any) applicable to the option shares and the maximum term
for which such option is to remain outstanding, and (iii) which eligible persons are to receive stock issuances under the Stock Issuance
Program, the time or times when such issuances are to be made, the number of shares to be issued to each grantee, the vesting schedule
(if any) applicable to the shares and the consideration for such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>V.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
STOCK SUBJECT TO THE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Shares of the Company&rsquo;s Common Stock shall be available for issuance under the Plan and shall be drawn from either the Company&rsquo;s
authorized but unissued shares of Common Stock or from reacquired shares of Common Stock, including shares repurchased by the Company
on the open market. The maximum number of shares of Common Stock which may be issued over the term of the Plan, as amended and restated,
shall not exceed 63,090,000 shares, subject to adjustment from time to time in accordance with the provisions of this Section V. The total
number of shares available under the Plan, as amended and restated, as of April 24, 2023 is 38,875,731. This amount consists of 34,135,014
shares reserved for awards already issued, 4,740,717 shares of Common Stock available for future issuance under the Plan, and the increase
of 7,000,000 shares of Common Stock authorized by the Board (subject to approval by the Company&rsquo;s stockholders at the Annual Meeting
of Stockholders on June 13, 2023).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In no event shall the number of shares of Common Stock for which any one individual participating in the Plan may receive options, separately
exercisable stock appreciation rights and direct stock issuances and RSUs exceed 1,500,000 shares of Common Stock in the aggregate in
any calendar year. For purposes of such limitation, however, no stock options granted prior to the date the Common Stock was first registered
under Section 12 of the 1934 Act (the &ldquo;Section 12(g) Registration Date&rdquo;) shall be taken into account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Should an outstanding option under this Plan expire or terminate for any reason prior to exercise in full, the shares subject to the portion
of the option not so exercised shall be available for subsequent option grant or direct stock issuances or RSUs under the Plan. Unvested
shares issued under the Plan and subsequently repurchased by the Company, at the original issue price paid per share, pursuant to the
Company&rsquo;s repurchase rights under the Plan, or shares underlying terminated RSUs, shall be added back to the number of shares of
Common Stock reserved for issuance under the Plan and shall accordingly be available for reissuance through one or more subsequent option
grants or direct stock issuances or RSUs under the Plan. However, shares subject to an award under the Plan may not again be made available
for issuance under the Plan if such shares are: (i) shares that were subject to a stock-settled stock appreciation right and were not
issued upon the net settlement or net exercise of such stock appreciation right, (ii) shares used to pay the exercise price of an option,
(iii) shares delivered to or withheld by the Company to pay the withholding taxes related an award, or (iv) shares repurchased on the
open market with the proceeds of an option exercise. Shares of Common Stock subject to any option surrendered for an appreciation distribution
under Section IV of Article Two or Section II.B.1.(iv) of Article Four shall not be available for subsequent issuance under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In the event any change is made to the Common Stock issuable under the Plan by reason of any stock split, stock dividend, recapitalization,
combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without receipt of consideration,
then appropriate adjustments shall be made to (i) the maximum number and/or class of securities issuable under the Plan, (ii) the maximum
number and/or class of securities for which any one individual participating in the Plan may be granted stock options, separately exercisable
stock appreciation rights, and direct stock issuances and RSUs under the Plan from and after the Section 12(g) Registration Date, (iii)
the number and/or class of securities and price per share in effect under each outstanding option and stock appreciation right under the
Plan, (iv) the number and/or class of securities in effect under each outstanding direct stock issuance and RSU under the Plan, and (v)
the number and/or class of securities for which grants are subsequently to be made per non-employee Board member under the Director Grant
Program. The purpose of such adjustments shall be to preclude the enlargement or dilution of rights and benefits under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The fair market value per share of Common Stock on any relevant date under the Plan shall be determined in accordance with the following
provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Common Stock is not at the time listed or admitted to trading on any national securities exchange but is traded in the over-the-counter
market, the fair market value shall be the mean between the highest bid and lowest asked prices (or, if such information is available,
the closing selling price) per share of Common Stock on the date in question in the over-the-counter market, as such prices are reported
on the Nasdaq National Market, the Nasdaq Global Select Market or any successor system. If there are no reported bid and asked prices
(or closing selling price) for the Common Stock on the date in question, then the mean between the highest bid price and lowest asked
price (or the closing selling price) on the last preceding date for which such quotations exist shall be determinative of fair market
value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Common Stock is at the time listed or admitted to trading on any national securities exchange, then the fair market value shall be
the closing selling price per share of Common Stock on the date in question on the securities exchange determined by the Plan Administrator
to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange.
If there is no reported sale of Common Stock on the exchange on the date in question, then the fair market value shall be the closing
selling price on the exchange on the last preceding date for which such quotation exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Common Stock is at the time neither listed nor admitted to trading on any securities exchange nor traded in the over-the-counter market,
then the fair market value shall be determined by the Plan Administrator after taking into account such factors as the Plan Administrator
shall deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>VI.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MINIMUM
VESTING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Notwithstanding any other provision
of this Plan to the contrary, in no event shall any award granted pursuant to this Plan vest prior to the twelve (12)-month anniversary
of the date of grant, other than in connection with the grantee&rsquo;s death or permanent disability or, to the extent permitted hereunder,
in connection with a Change in Control (provided that this limitation shall not apply with respect to up to five percent (5%) of the shares
of Common Stock available for issuance under this Plan following approval of the Plan at the Company&rsquo;s Annual Meeting of Stockholders
on June 13, 2023). The minimum vesting period set forth in this Section VI may not be waived or superseded by any provision in an award
or other agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
Two</B></FONT><B><BR>
<U>DISCRETIONARY OPTION GRANT PROGRAM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
TERMS AND CONDITIONS OF OPTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Options granted pursuant to
this Article Two shall be authorized by action of the Plan Administrator and may, at the Plan Administrator&rsquo;s discretion, be either
Incentive Options or non-statutory options. Individuals who are not Employees may only be granted non-statutory options under this Article
Two. Each option granted shall be evidenced by one or more instruments in the form approved by the Plan Administrator. Each such instrument
shall, however, comply with the terms and conditions specified below, and each instrument evidencing an Incentive Option shall, in addition,
be subject to the applicable provisions of Section II of this Article Two.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Option Price</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The option price per share shall be fixed by the Plan Administrator. In no event, however, shall the option price per share be less than
one hundred percent (100%) of the fair market value per share of Common Stock on the date of the option grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The option price shall become immediately due upon exercise of the option and shall, subject to the provisions of Section IV of this Article
Two and the instrument evidencing the grant, be payable through one of the following methods (or a combination thereof):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;full
payment in cash or check drawn to the Company&rsquo;s order;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;full
payment in shares of Common Stock held by the optionee for the requisite period necessary to avoid a charge to the Company&rsquo;s earnings
for financial reporting purposes and valued at fair market value on the Exercise Date (as such term is defined below);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;full
payment through a combination of shares of Common Stock held by the optionee for the requisite period necessary to avoid a charge to the
Company&rsquo;s earnings for financial reporting purposes and valued at fair market value on the Exercise Date and cash or cash equivalent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;full
payment through a broker-dealer sale and remittance procedure pursuant to which the optionee (I) shall provide irrevocable written instructions
to a designated brokerage firm to effect the immediate sale of the purchased shares and remit to the Company, out of the sale proceeds
available on the settlement date, sufficient funds to cover the aggregate option price payable for the purchased shares plus all applicable
Federal and State income and employment taxes required to be withheld by the Company in connection with such purchase and (II) shall provide
written directives to the Company to deliver the certificates for the purchased shares directly to such brokerage firm in order to complete
the sale transaction; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
other method as permitted by the Plan Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this subparagraph
2, the Exercise Date shall be the date on which written notice of the option exercise is delivered to the Company. Except to the extent
the sale and remittance procedure is utilized in connection with the exercise of the option, payment of the option price for the purchased
shares must accompany such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Term and Exercise of Options</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Each option granted under
this Article Two shall be exercisable at such time or times, during such period, and for such number of shares as shall be determined
by the Plan Administrator and set forth in the instrument evidencing the option grant. No such option, however, shall have a maximum term
in excess of ten (10) years from the grant date. During the lifetime of the optionee, the option, together with any stock appreciation
rights pertaining to such option, shall be exercisable only by the optionee and shall not be assignable or transferable by the optionee
except for a transfer of the option by will or by the laws of descent and distribution following the optionee&rsquo;s death and, for the
avoidance of doubt, may not be transferred to a third party for cash or other value. However, the Plan Administrator shall have the discretion
to provide that a non-statutory option may, in connection with the optionee&rsquo;s estate plan, be assigned in whole or in part during
the optionee&rsquo;s lifetime either (i) as a gift to one or more members of optionee&rsquo;s immediate family, to a trust in which optionee
and/or one or more such family members hold more than fifty percent (50%) of the beneficial interest or an entity in which more than fifty
percent (50%) of the voting interests are owned by optionee and/or one or more such family members, or (ii) pursuant to a domestic relations
order. The assigned portion shall be exercisable only by the person or persons who acquire a proprietary interest in the option pursuant
to such assignment. The terms applicable to the assigned portion shall be the same as those in effect for this option immediately prior
to such assignment and shall be set forth in such documents issued to the assignee as the Plan Administrator may deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Termination of Service</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Except to the extent otherwise provided pursuant to Section V of this Article Two or pursuant to an applicable award agreement, the following
provisions shall govern the exercise period applicable to any options held by the optionee at the time of cessation of Service or death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
the optionee cease to remain in Service for any reason other than death or permanent disability, then the period for which each outstanding
option held by such optionee is to remain exercisable shall be limited to the three (3)-month period following the date of such cessation
of Service. However, should optionee die during the three (3)-month period following his or her cessation of Service, the personal representative
of the optionee&rsquo;s estate or the person or persons to whom the option is transferred pursuant to the optionee&rsquo;s will or in
accordance with the laws of descent and distribution shall have a twelve (12)-month period following the date of the optionee&rsquo;s
death during which to exercise such option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event such Service terminates by reason of permanent disability (as defined in Section 22(e)(3) of the Internal Revenue Code), then
the period for which each outstanding option held by the optionee is to remain exercisable shall be limited to the twelve (12)-month period
following the date of such cessation of Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
the optionee, after completing five (5) full years of Service, die while in Service, then the exercisability of each of his or her outstanding
options shall automatically accelerate so that each such option shall become fully exercisable with respect to the total number of shares
of Common Stock at the time subject to such option and may be exercised for all or any portion of such shares. The personal representative
of the optionee&rsquo;s estate or the person or persons to whom the option is transferred pursuant to the optionee&rsquo;s will or in
accordance with the laws of descent and distribution shall have a twelve (12)-month period following the date of the optionee&rsquo;s
death during which to exercise such option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event such Service terminates by reason of death prior to the optionee obtaining five (5) full years of Service, then the period for
which each outstanding vested option held by the optionee at the time of death shall be exercisable by the optionee&rsquo;s estate or
the person or persons to whom the option is transferred pursuant to the optionee&rsquo;s will shall be limited to the twelve (12)-month
period following the date of the optionee&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
no circumstances, however, shall any such option be exercisable after the specified expiration date of the option term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
such option shall, during such limited exercise period, be exercisable for any or all of the shares for which the option is exercisable
on the date of the optionee&rsquo;s cessation of Service. Upon the expiration of such limited exercise period or (if earlier) upon the
expiration of the option term, the option shall terminate and cease to be exercisable. However, each outstanding option shall immediately
terminate and cease to remain outstanding, at the time of the optionee&rsquo;s cessation of Service, with respect to any shares for which
the option is not otherwise at that time exercisable or in which the optionee is not otherwise vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
(i) the optionee&rsquo;s Service be terminated for misconduct (including, but not limited to, any act of dishonesty, willful misconduct,
fraud or embezzlement) or (ii) the optionee make any unauthorized use or disclosure of confidential information or trade secrets of the
Company or its parent or subsidiary corporations, then in any such event all outstanding options held by the optionee under this Article
Two shall terminate immediately and cease to be exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Plan Administrator shall have complete discretion, exercisable either at the time the option is granted or at any time while the option
remains outstanding, to permit one or more options held by the optionee under this Article Two to be exercised, during the limited period
of exercisability provided under subparagraph 1 above, not only with respect to the number of shares for which each such option is exercisable
at the time of the optionee&rsquo;s cessation of Service but also with respect to one or more subsequent installments of purchasable shares
for which the option would otherwise have become exercisable had such cessation of Service not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For purposes of the foregoing provisions of this Section I.C (and for all other purposes under the Plan):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
optionee shall be deemed to remain in the <B>Service</B> of the Company for so long as such individual renders services on a periodic
basis to the Company (or any parent or subsidiary corporation) in the capacity of an Employee, a non-employee member of the board of directors
or an independent consultant or advisor, unless the agreement evidencing the applicable option grant specifically states otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
optionee shall be considered to be an <B>Employee </B>for so long as such individual remains in the employ of the Company or one or more
of its parent or subsidiary corporations, subject to the control and direction of the employer entity not only as to the work to be performed
but also as to the manner and method of performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Stockholder Rights</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">An optionee shall have no
stockholder rights with respect to any shares covered by the option until such individual shall have exercised the option and paid the
option price for the purchased shares. Without limitation, an optionee shall not have any right to receive dividends with respect to an
unexercised option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>No Repricing</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">No option or stock appreciation
right may be repriced, regranted through cancellation, including cancellation in exchange for cash or other awards, or otherwise amended
to reduce its option price or exercise price (other than with respect to adjustments made in connection with a transaction or other change
in the Company&rsquo;s capitalization as permitted under this Plan) without the approval of the stockholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Repurchase Rights</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">The shares of Common Stock
acquired upon the exercise of options granted under this Article Two may be subject to repurchase by the Company in accordance with the
following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Plan Administrator shall have the discretion to grant options which are exercisable for unvested shares of Common Stock under this Article
Two. Should the optionee cease Service while holding such unvested shares, the Company shall have the right to repurchase any or all those
unvested shares at the option price paid per share. The terms and conditions upon which such repurchase right shall be exercisable (including
the period and procedure for exercise and the appropriate vesting schedule for the purchased shares) shall be established by the Plan
Administrator and set forth in the instrument evidencing such repurchase right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of the Company&rsquo;s outstanding repurchase rights shall automatically terminate, and all shares subject to such terminated rights shall
immediately vest in full, upon the occurrence of any Corporate Transaction under Section III of this Article Two, except to the extent:
(i) any such repurchase right is expressly assigned to the successor corporation (or parent thereof) in connection with the Corporate
Transaction or (ii) such termination is precluded by other limitations imposed by the Plan Administrator at the time the repurchase right
is issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Plan Administrator shall have the discretionary authority, exercisable either before or after the optionee&rsquo;s cessation of Service,
to cancel the Company&rsquo;s outstanding repurchase rights with respect to one or more shares purchased or purchasable by the optionee
under this Discretionary Option Grant Program and thereby accelerate the vesting of such shares in whole or in part at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>II.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
INCENTIVE OPTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The terms and conditions specified
below shall be applicable to all Incentive Options granted under this Article Two. Incentive Options may only be granted to individuals
who are Employees of the Company. Options which are specifically designated as &ldquo;non-statutory&rdquo; options when issued under the
Plan shall not be subject to such terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Dollar Limitation</U></B>. The aggregate fair market value (determined as of the respective date or dates of grant) of the Common
Stock for which one or more options granted to any Employee under this Plan (or any other option plan of the Company or its parent or
subsidiary corporations) may for the first time become exercisable as incentive stock options under the Federal tax laws during any one
calendar year shall not exceed the sum of One Hundred Thousand Dollars ($100,000). To the extent the Employee holds two or more such options
which become exercisable for the first time in the same calendar year, the foregoing limitation on the exercisability of such options
as incentive stock options under the Federal tax laws shall be applied on the basis of the order in which such options are granted. Should
the number of shares of Common Stock for which any Incentive Option first becomes exercisable in any calendar year exceed the applicable
One Hundred Thousand Dollar ($100,000) limitation, then that option may nevertheless be exercised in such calendar year for the excess
number of shares as a non-statutory option under the Federal tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>10% Stockholder</U></B>. If any individual to whom an Incentive Option is granted is the owner of stock (as determined under Section
424(d) of the Internal Revenue Code) possessing 10% or more of the total combined voting power of all classes of stock of the Company
or any one of its parent or subsidiary corporations, then the option price per share shall not be less than one hundred and ten percent
(110%) of the fair market value per share of Common Stock on the grant date, and the option term shall not exceed five (5) years, measured
from the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Termination of Employment</U></B>. Any portion of an Incentive Option that remains outstanding (by reason of the optionee remaining
in the Service of the Company, pursuant to the Plan Administrator&rsquo;s exercise of discretion under Section V of this Article Two,
or otherwise) more than 3 months following the date an optionee ceases to be an Employee of the Company shall thereafter be exercisable
as a non-statutory option under federal tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Except as modified by the preceding
provisions of this Section II, the provisions of Articles One, Two and Five of the Plan shall apply to all Incentive Options granted hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>III.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CORPORATE TRANSACTIONS/CHANGES IN CONTROL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For purposes of this Section III (and for all other purposes under the Plan), a Corporate Transaction shall be deemed to occur in the
event of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
merger or consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of which is to
change the State of the Company&rsquo;s incorporation,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
sale, transfer or other disposition of all or substantially all of the assets of the Company in liquidation or dissolution of the Company,
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
reverse merger in which the Company is the surviving entity but in which securities possessing more than fifty percent (50%) of the total
combined voting power of the Company&rsquo;s outstanding securities are transferred to a person or persons different from the persons
holding those securities immediately prior to such merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exercisability of each option outstanding
under this Article Two that was granted before April 3, 2017 shall automatically accelerate so that each such option shall, immediately
prior to the specified effective date for the Corporate Transaction, become fully exercisable with respect to the total number of shares
of Common Stock at the time subject to such option and may be exercised for all or any portion of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Immediately
after the consummation of the Corporate Transaction, all outstanding options under this Article Two shall fully vest, terminate and cease
to be outstanding, except to the extent continued or assumed (as applicable) by the Company or the successor corporation or its parent
company. The Plan Administrator shall have complete discretion to provide, on such terms and conditions as it sees fit, for a cash payment
to be made to any optionee on account of any option terminated in accordance with this paragraph, in an amount equal to the excess (if
any) of (A) the fair market value of the shares subject to the option as of the date of the Corporate Transaction, over (B) the aggregate
exercise price of the option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Each
outstanding option under this Article Two which is assumed in connection with the Corporate Transaction or is otherwise to continue in
effect shall be appropriately adjusted, immediately after such Corporate Transaction, to apply and pertain to the number and class of
securities which would have been issued to the option holder, in consummation of such Corporate Transaction, had such person exercised
the option immediately prior to such Corporate Transaction. Appropriate adjustments shall also be made to the option price payable per
share, <U>provided</U> the aggregate option price payable for such securities shall remain the same. In addition, the class and number
of securities available for issuance under the Plan following the consummation of the Corporate Transaction shall be appropriately adjusted.
Any such options that are so continued or assumed in connection with a Corporate Transaction shall be treated as follows: if the grantee&rsquo;s
employment is terminated by the Company without Cause or the grantee resigns due to a Constructive Termination, in either case within
the ninety (90) day period preceding or the two (2) year period following the Corporate Transaction, the exercisability of such option
shall automatically accelerate, and the Company&rsquo;s outstanding repurchase rights under this Article Two shall immediately terminate;
provided, however, that if the Company, the acquiror or successor refuses to continue (or, as applicable, assume) the option in connection
with the Corporate Transaction, the exercisability of such option under this Article Two shall automatically accelerate, and the Company&rsquo;s
outstanding repurchase rights under this Article Two shall immediately terminate upon the occurrence of such Corporate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The
grant of options under this Article Two shall in no way affect the right of the Company to adjust, reclassify, reorganize or otherwise
change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business
or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In
the event of a Change in Control: (1) options granted under this Article Two prior to May 23, 2016 shall be subject to the provisions
of the Plan as in effect prior to such date, and (2) options granted on or after May 23, 2016 shall be treated as follows: if the grantee&rsquo;s
employment is terminated by the Company without Cause or the grantee resigns due to a Constructive Termination, in either case within
the ninety (90) day period preceding or the two (2) year period following the Change in Control, the exercisability of such option shall
automatically accelerate, and the Company&rsquo;s outstanding repurchase rights under this Article Two shall immediately terminate; provided,
however, that if the acquiror or successor refuses to assume the option in connection with the Change in Control, the exercisability of
such option under this Article Two shall automatically accelerate, and the Company&rsquo;s outstanding repurchase rights under this Article
Two shall immediately terminate upon the occurrence of such Change in Control. In the event that the acquiror or successor refuses to
assume the option in connection with the Change in Control, the Plan Administrator shall have complete discretion to provide, on such
terms and conditions as it sees fit, for a cash payment to be made to any optionee on account of any option terminated in accordance with
this paragraph, in an amount equal to the excess (if any) of (A) the fair market value of the shares subject to the option as of the date
of the Change in Control, over (B) the aggregate exercise price of the option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">F.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For
purposes of this Section III (and for all other purposes under the Plan), a Change in Control shall be deemed to occur in the event:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
person or related group of persons (other than the Company or a person that directly or indirectly controls, is controlled by, or is under
common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act)
of securities possessing more than fifty percent (50%) of the total combined voting power of the Company&rsquo;s outstanding securities
pursuant to a tender or exchange offer made directly to the Company&rsquo;s stockholders; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
is a change in the composition of the Board over a period of twenty-four (24) consecutive months or less such that a majority of the Board
members (rounded up to the next whole number) ceases, by reason of one or more contested elections for Board membership, to be comprised
of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated
for election as Board members during such period by at least two-thirds of the Board members described in clause (A) who were still in
office at the time such election or nomination was approved by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">G.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All options accelerated in connection with the Corporate Transaction or Change in Control (either at the time of the Corporate Transaction
or Change in Control or as otherwise provided in this Section III) shall remain fully exercisable until the expiration or sooner termination
of the option term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">H.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The portion of any Incentive Option accelerated under this Section III in connection with a Corporate Transaction or Change in Control
shall remain exercisable as an incentive stock option under the Federal tax laws only to the extent the dollar limitation of Section II
of this Article Two is not exceeded. To the extent such dollar limitation is exceeded, the accelerated portion of such option shall be
exercisable as a non-statutory option under the Federal tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For purposes of this Article Two and for purposes of Article Three:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Cause&rdquo; means, unless otherwise provided in the applicable award agreement, the Company&rsquo;s termination of the grantee&rsquo;s
employment for any of the following reasons: (i) failure or refusal to comply in any material respect with lawful policies, standards
or regulations of the Company; (ii) a violation of a federal or state law or regulation applicable to the business of the Company; (iii)
conviction or plea of no contest to a felony under the laws of the United States or any State; (iv) fraud or misappropriation of property
belonging to the Company or its affiliates; (v) a breach in any material respect of the terms of any confidentiality, invention assignment
or proprietary information agreement with the Company or with a former employer, (vi) failure to satisfactorily perform the grantee&rsquo;s
duties after having received written notice of such failure and at least thirty (30) days to cure such failure, or (vii) misconduct or
gross negligence in connection with the performance of the grantee&rsquo;s duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&ldquo;Constructive Termination&rdquo; means, unless otherwise provided in the applicable award agreement, the grantee&rsquo;s resignation
of employment with the Company within ninety (90) days of the occurrence of any of the following: (i) a material reduction in the grantee&rsquo;s
responsibilities; (ii) a material reduction in the grantee&rsquo;s base salary; or (iii) a relocation of the grantee&rsquo;s principal
office to a location more than 50 miles from the location of the grantee&rsquo;s existing principal office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IV.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
STOCK APPRECIATION RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Provided and
only if the Plan Administrator determines in its discretion to implement the stock appreciation right provisions of this Section IV, one
or more optionees may be granted the right, exercisable upon such terms and conditions as the Plan Administrator may establish, to surrender
all or part of an unexercised option granted under this Article Two in exchange for a distribution from the Company in an amount equal
to the excess of (i) the fair market value (on the option surrender date) of the number of shares in which the optionee is at the time
vested under the surrendered option (or surrendered portion thereof) over (ii) the aggregate option price payable for such vested shares.
The distribution may be made in shares of Common Stock valued at fair market value on the option surrender date, in cash, or partly in
shares and partly in cash, as the Plan Administrator shall determine in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The
shares of Common Stock subject to any option surrendered for an appreciation distribution pursuant to this Section IV shall not be available
for subsequent option grant under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Stockholder
Rights</U></B>. A stock appreciation right holder shall have no stockholder rights with respect to any shares covered by the stock appreciation
right until such individual shall have exercised the stock appreciation right and received the acquired shares. Without limitation, a
stock appreciation right holder shall not have any right to receive dividends with respect to a stock appreciation right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>V.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
EXTENSION OF EXERCISE PERIOD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Plan Administrator shall
have full power and authority, exercisable either at the time the option is granted or at any time while the option remains outstanding,
to extend the period of time for which any option granted under this Article Two is to remain exercisable following the optionee&rsquo;s
cessation of Service or death from the limited period in effect under Section I.C.1 of Article Two to such greater period of time as the
Plan Administrator shall deem appropriate; <U>provided</U>, however, that in no event shall such option be exercisable after the specified
expiration date of the option term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
Three</B></FONT><B><BR>
<U>STOCK ISSUANCE PROGRAM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
STOCK ISSUANCE TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Shares of Common Stock may be
issued under the Stock Issuance Program through direct and immediate issuances without any intervening option grants. Each such stock
issuance shall be evidenced by a Stock Issuance Agreement which complies with the terms specified below. Shares of Common Stock may also
be issued under the Stock Issuance Program pursuant to restricted stock units (&ldquo;RSUs&rdquo;), which are awards granted to eligible
individuals that entitle them to shares of Common Stock (or cash in lieu thereof) in the future following the satisfaction of vesting
conditions imposed by the Plan Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Vesting Provisions</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Plan
Administrator may issue shares of Common Stock under the Stock Issuance Program which are to vest in one or more installments over the
grantee&rsquo;s period of Service or upon attainment of specified performance objectives. Alternatively, the Plan Administrator may issue
RSUs under the Stock Issuance Program which shall entitle the recipient to receive a specified number of shares of Common Stock upon the
attainment of one or more Service and/or performance goals established by the Plan Administrator. Upon the attainment of such Service
and/or performance goals, fully-vested shares of Common Stock shall be issued in satisfaction of those RSUs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Any
new, substituted or additional securities or other property (including money paid other than as a regular cash dividend) issued by reason
of any stock dividend, stock split, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding
Common Stock as a class without the Company&rsquo;s receipt of consideration, shall be issued or set aside with respect to the shares
of unvested Common Stock granted to a grantee or subject to a grantee&rsquo;s RSUs, subject to (i) the same vesting requirements applicable
to the grantee&rsquo;s unvested shares of Common Stock or RSUs, and (ii) such escrow arrangements as the Plan Administrator shall deem
appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The
grantee shall have full stockholder rights with respect to any shares of Common Stock issued to the grantee under the Stock Issuance Program,
whether or not the grantee&rsquo;s interest in those shares is vested, except that the grantee shall not have dividend rights with respect
to such shares prior to the vesting of such shares. However, the Plan Administrator may provide for a grantee to receive one or more dividend
equivalents with respect to such shares, entitling the grantee to all regular cash dividends payable on such shares of Common Stock, which
amounts shall be (i) subject to the same vesting requirements applicable to the shares of Common Stock granted hereunder, and (ii) payable
upon vesting of the shares to which such dividend equivalents relate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The grantee
shall not have any stockholder rights with respect to any shares of Common Stock subject to an RSU. However, the Plan Administrator may
provide for a grantee to receive one or more dividend equivalents with respect to such shares, entitling the grantee to all regular cash
dividends payable on the shares of Common Stock underlying the RSU, which amounts shall be (i) subject to the same vesting requirements
applicable to the shares of Common Stock underlying the RSU, and (ii) payable upon issuance of the shares to which such dividend equivalents
relate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Should
the grantee cease to remain in Service while holding one or more unvested shares of Common Stock issued under the Stock Issuance Program
or should the performance objectives not be attained with respect to one or more such unvested shares of Common Stock, then those shares
shall be immediately surrendered to the Company for cancellation, and the grantee shall have no further stockholder rights with respect
to those shares. To the extent the surrendered shares were previously issued to the grantee for consideration paid in cash, the Company
shall repay to the grantee the cash consideration paid for the surrendered shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Except as prohibited
by the last sentence of paragraph 1 above, the Plan Administrator may in its discretion waive the surrender and cancellation of one or
more unvested shares of Common Stock which would otherwise occur upon the cessation of the grantee&rsquo;s Service or the non-attainment
of the performance objectives applicable to those shares. Such waiver shall result in the immediate vesting of the grantee&rsquo;s interest
in the shares of Common Stock as to which the waiver applies. Such waiver may be effected at any time, whether before or after the grantee&rsquo;s
cessation of Service or the attainment or non-attainment of the applicable performance objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Outstanding
RSUs under the Stock Issuance Program shall automatically terminate, and no shares of Common Stock shall actually be issued in satisfaction
of those awards, if the Service and/or performance goals established for such awards are not attained. The Plan Administrator, however,
shall, except as prohibited by the last sentence of paragraph 1 above, have the discretionary authority to issue shares of Common Stock
in satisfaction of one or more outstanding RSUs as to which the designated Service and/or performance goals are not attained. Such authority
may be exercised at any time, whether before or after the grantee&rsquo;s cessation of Service or the attainment or non-attainment of
the applicable performance objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>II.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CORPORATE TRANSACTION/CHANGE IN CONTROL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All of the
Company&rsquo;s outstanding repurchase rights under the Stock Issuance Program shall terminate automatically, and all the shares of Common
Stock subject to those terminated rights shall immediately vest in full, in the event of any Corporate Transaction, except to the extent
(i) those repurchase rights are to be assigned to the successor corporation (or parent thereof) in connection with such Corporate Transaction,
or (ii) such accelerated vesting is precluded by other limitations imposed in the Stock Issuance Agreement, unless the Plan Administrator
determines to waive such limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Each
award which is assigned in connection with (or is otherwise to continue in effect after) a Corporate Transaction shall be appropriately
adjusted such that it shall apply and pertain to the number and class of securities issued to the grantee in consummation of the Corporate
Transaction with respect to the shares granted to grantee under this Article Three.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In the
event of a Change in Control, shares of restricted stock and RSUs shall be treated as follows: if the grantee&rsquo;s employment is terminated
by the Company without Cause or the grantee resigns due to a Constructive Termination, in either case within the ninety (90) day period
preceding or the two (2) year period following the Change in Control, the vesting of such restricted stock and RSUs shall automatically
accelerate (and all of the shares of Common Stock subject to such RSUs shall be issued to grantees), and the Company&rsquo;s outstanding
repurchase rights under this Article Three shall immediately terminate; provided, however, that if the acquiror or successor refuses to
assume the shares of restricted stock or RSUs or substitute an award of equivalent value (as determined by the Committee in its discretion)
in connection with the Change in Control, the vesting of such restricted stock or RSUs under this Article Three shall automatically accelerate
(and all of the shares of Common Stock subject to such RSUs shall be issued to grantees). To the extent any shares of restricted stock
or RSUs vest in whole or in part based on the achievement of performance criteria, the amount that shall vest in accordance with the proviso
to clause (2) of the immediately-preceding sentence shall vest based on the higher of actual performance goal attainment through the date
of the Change in Control or a prorated amount using target performance and based on the time elapsed in the performance period as of the
date of the Change in Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>III.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
STOCKHOLDER RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Individuals
who are granted shares of Common Stock pursuant to this Article Three shall be the owners of such shares for all purposes while holding
such Common Stock, and may exercise full voting rights with respect to those shares at all times while held by the individuals. Individuals
who have been granted RSUs shall have no voting rights with respect to Common Stock underlying RSUs unless and until such Common Stock
is reflected as issued and outstanding shares on the Company&rsquo;s stock ledger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Individuals
who are granted shares of Common Stock pursuant to this Article Three shall not have dividend rights with respect to such shares prior
to the vesting of such shares. However, the Plan Administrator may provide for a grantee to receive one or more dividend equivalents with
respect to such shares, entitling the grantee to all regular cash dividends payable on such shares of Common Stock, which amounts shall
be (i) subject to the same vesting requirements applicable to the shares of Common Stock granted hereunder, and (ii) payable upon vesting
of the shares to which such dividend equivalents relate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IV.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
SHARE ESCROW / LEGENDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Unvested shares may, in the
Plan Administrator&rsquo;s discretion, be held in escrow by the Company until the grantee&rsquo;s interest in such shares vests or may
be issued directly to the grantee with restrictive legends on the certificates evidencing those unvested shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
Four</B></FONT><B><BR>
<U>DIRECTOR GRANT PROGRAM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ELIGIBILITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The individuals eligible to
receive grants pursuant to the provisions of this Article Four shall be (i) those individuals who, after the effective date of this amendment
and restatement, first become non-employee Board members, whether through appointment by the Board, election by the Company&rsquo;s stockholders,
or by continuing to serve as a Board member after ceasing to be employed by the Company, and (ii) those individuals already serving as
non-employee Board members on the effective date of this amendment and restatement. As used herein, a &ldquo;non-employee&rdquo; Board
member is any Board member who is not employed by the Company on the date in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>II.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
TERMS AND CONDITIONS OF DIRECTOR GRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Grants</U></B>. Grants under this Article Four shall be made pursuant to a Director Compensation Policy adopted by the Board (the
&ldquo;Director Compensation Policy&rdquo;) and may be in the form of non-statutory options, RSUs, shares of Common Stock, other awards
issuable under the Plan or a combination thereof, as determined by the Committee. In no event shall the aggregate grant date fair value
(calculated in accordance with FASB ASC Topic 718 ) of all awards granted under the Plan during any calendar year to any non-employee
Board member (excluding any awards granted at the election of a non-employee Board member in lieu of all or any portion of cash retainers
or fees otherwise payable to non-employee Board members in cash), together with the amount of any cash fees or retainers paid to such
non-employee Board members during such calendar year with respect to such individual&rsquo;s service as a non-employee Board member, exceed
$750,000 (or, for a non-employee Board member who first joins the Board, $1,000,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B><U>Terms and Conditions of Grants</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I><U>Options</U>.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term</U>. Each option granted under this Article Four shall be exercisable at such time or times, during such period, and for
such number of shares as shall be set forth in the Director Compensation Policy or as otherwise determined by the Plan Administrator and
set forth in the instrument evidencing the option grant. No such option, however, shall have a maximum term in excess of ten (10) years
from the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Option Price</U>. The option price per share shall be fixed by the Plan Administrator. In no event, however, shall the option
price per share be less than one hundred percent (100%) of the fair market value per share of Common Stock on the date of the option grant.
The option price shall become immediately due upon exercise of the option and shall, subject to Section II.B.1.(iv) of this Article Four
and the instrument evidencing the grant, be payable in any manner set forth in Section I.A.2 of Article Two.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Transferability</U>. During the lifetime of the optionee, each option grant, together with any limited stock appreciation
right pertaining to such option, shall be exercisable only by the optionee and shall not be assignable or transferable by the optionee,
except to the extent such option or the limited stock appreciation right is assigned or transferred (i) by will or by the laws of descent
and distribution following the optionee&rsquo;s death, or (ii) during optionee&rsquo;s lifetime either (A) as a gift in connection with
the optionee&rsquo;s estate plan to one or more members of optionee&rsquo;s immediate family, to a trust in which optionee and/or one
or more such family members hold more than fifty percent (50%) of the beneficial interest or to an entity in which more than fifty percent
(50%) of the voting interests are owned by optionee and/or one or more such family members, or (B) pursuant to a domestic relations order.
The portion of any option assigned or transferred during optionee&rsquo;s lifetime shall be exercisable only by the person or persons
who acquire a proprietary interest in the option pursuant to such assignment. The terms applicable to the assigned portion shall be the
same as those in effect for this option immediately prior to such assignment and shall be set forth in such documents issued to the assignee
as the Plan Administrator may deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Appreciation Rights</U>. With respect to each option granted under this Article Four, each optionee shall have the right
to surrender all or part of the option (to the extent not then exercised) in exchange for a distribution from the Company in an amount
equal to the excess of (i) the fair market value (on the option surrender date) of the number of shares in which the grantee is at the
time vested under the surrendered option (or surrendered portion thereof) over (ii) the aggregate option price payable for such vested
shares. The distribution shall be made in shares of Common Stock valued at fair market value on the option surrender date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Repricing</U>. No option or stock appreciation right may be repriced, regranted through cancellation, including cancellation
in exchange for cash or other awards, or otherwise amended to reduce its option price or exercise price (other than with respect to adjustments
made in connection with a transaction or other change in the Company&rsquo;s capitalization as permitted under this Plan) without the
approval of the stockholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I><U>Grants
Generally</U></I>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stockholder Rights</U>. The holder of an option grant under this Article Four shall have none of the rights of a stockholder
with respect to any shares subject to such option until such individual shall have exercised the option and paid the exercise price for
the purchased shares, and the holder of RSUs granted under this Article Four shall have none of the rights of a stockholder with respect
to any shares subject to such RSUs until shares have been delivered in settlement thereof. Without limitation, a grantee shall not have
any right to receive dividends with respect to an unexercised option or unsettled RSUs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Corporate Transactions/Changes in Control</U>. In connection with a Corporate Transaction or a Change in Control, grants under
this Article Four shall be treated in the manner specified in Article Two (with respect to options) or Article Three (with respect to
shares of Common Stock and RSUs), as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the terms of the Plan, the terms and conditions of the grants under this Article Four shall be determined by the Plan
Administrator consistent with the Director Compensation Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
Five</B></FONT><B><BR>
<U>PERFORMANCE GOALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
GENERAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Plan Administrator may establish
performance criteria and level of achievement versus such criteria that shall determine the number of shares of Common Stock or RSUs to
be granted, retained, vested, issued or issuable under or in settlement of or the amount payable pursuant to an award hereunder. In addition,
the Plan Administrator may specify that an award or a portion of an award shall be subject to measures based on one or more performance
criteria selected by the Committee and specified at the time the award is granted. The Committee shall certify the extent to which any
performance criteria have been satisfied, and the amount payable as a result thereof, prior to payment, settlement or vesting of any award
subject thereto. Notwithstanding satisfaction of any performance goals, the number of shares of Common Stock issued under or the amount
paid under an award may, to the extent specified in the applicable award agreement, be reduced by the Committee on the basis of such further
considerations as the Committee in its sole discretion shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>II.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
PERFORMANCE CRITERIA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">For purposes of this Plan, performance
criteria may include, among others, any one or more of the following performance criteria, either individually, alternatively or in any
combination, applied to either the Company as a whole or to a business unit or subsidiary, either individually, alternatively or in any
combination, and measured either quarterly, annually or cumulatively over a period of years, on an absolute basis or relative to a pre-established
target, to previous years&rsquo; results or to a designated comparison group, in each case as specified by the Committee: (i) revenue
growth; (ii) earnings before interest, taxes, depreciation and amortization; (iii) earnings before interest, taxes and amortization; (iv)
operating income; (v) pre- or after-tax income; (vi) cash flow; (vii) cash flow per share; (viii) net income; (ix) earnings per share;
(x) return on equity; (xi) return on invested capital; (xii) return on assets; (xiii) economic value added (or an equivalent metric);
(xiv) share price performance; (xv) total shareholder return; (xvi) improvement in or attainment of expense levels; (xvii) improvement
in or attainment of working capital levels; (xviii) debt reduction; (xix) progress for advancing drug discovery and/or drug development
programs; or (xx) implementation, completion or attainment of measurable objectives with respect to research, development, manufacturing,
commercialization, products or projects, or production volume levels. The Committee (A) shall appropriately adjust any evaluation of performance
under applicable performance criteria to eliminate the effects of charges for restructurings, discontinued operations, extraordinary items
and all items of gain, loss or expense determined to be extraordinary or unusual in nature or related to the acquisition or disposal of
a segment of a business or related to a change in accounting principle all as determined in accordance with standards established by opinion
No. 30 of the Accounting Principles Board (APB Opinion No. 30) or other applicable or successor accounting provisions, as well as the
cumulative effect of accounting changes, in each case as determined in accordance with generally accepted accounting principles or identified
in the Company&rsquo;s financial statements or notes to the financial statements, and (B) may appropriately adjust any evaluation of performance
under applicable performance criteria to exclude any of the following events that occurs during a performance period: (i) asset write-downs,
(ii) litigation, claims, judgments or settlements, (iii) the effect of changes in tax law or other such laws or provisions affecting reported
results, (iv) the adverse effect of work stoppages or slowdowns, (v) accruals for reorganization and restructuring programs and (vi) accruals
of any amounts for payment under this Plan or any other compensation arrangement maintained by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article
Six</B></FONT><B><BR>
<U>MISCELLANEOUS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
AMENDMENT OF THE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Board shall have complete
and exclusive power and authority to amend or modify the Plan in any or all respects whatsoever. However, no such amendment or modification
shall, without the consent of the holders, adversely affect rights and obligations with respect to options at the time outstanding under
the Plan. In addition, certain amendments may require stockholder approval pursuant to applicable laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>II.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
TAX WITHHOLDING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company&rsquo;s obligation to deliver shares or cash upon the exercise of stock options or stock appreciation rights or upon the grant
or vesting of direct stock issuances or RSUs under the Plan shall be subject to the satisfaction of all applicable Federal, State and
local income and employment tax withholding requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Plan Administrator may, in its discretion and upon such terms and conditions as it may deem appropriate, provide any or all
holders of outstanding options or stock issuances under the Plan (other than the grants under Article Four) with the election to have
the Company withhold, from the shares of Common Stock otherwise issuable upon the exercise or vesting of such awards, a whole number of
such shares with an aggregate fair market value equal to the minimum amount necessary (or, if determined by the Plan Administrator in
its discretion and to the extent adverse accounting treatment does not result, at the maximum applicable individual statutory tax rates)
to satisfy the Federal, State and local income and employment tax withholdings (the &ldquo;Taxes&rdquo;) incurred in connection with the
acquisition or vesting of such shares. In lieu of such direct withholding, one or more grantees may also be granted the right to deliver
whole shares of Common Stock to the Company in satisfaction of such Taxes. Any withheld or delivered shares shall be valued at their fair
market value on the applicable determination date for such Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>III.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
EFFECTIVE DATE AND TERM OF PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Plan,
as amended and restated, shall be effective on the date specified in the Board of Directors resolution adopting the Plan. Except as provided
below, each option issued and outstanding under the Plan immediately prior to such effective date shall continue to be governed solely
by the terms and conditions of the agreement evidencing such grant, and nothing in this restatement of the Plan shall be deemed to affect
or otherwise modify the rights or obligations of the holders of such options with respect to their acquisition of shares of Common Stock
thereunder. The Plan Administrator shall, however, have full power and authority, under such circumstances as the Plan Administrator may
deem appropriate (but in accordance with Section I of this Article Five), to extend one or more features of this amendment and restatement
to any options outstanding on the effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Unless
sooner terminated in accordance with the other provisions of this Plan, the Plan shall terminate upon the <U>earlier</U> of (i) ten (10)
years following the date this amendment and restatement of the Plan is approved by the Board or (ii) the date on which all shares available
for issuance under the Plan shall have been issued or cancelled pursuant to the exercise, surrender or cash-out of the options granted
hereunder. If the date of termination is determined under clause (i) above, then any options or stock issuances outstanding on such date
shall continue to have force and effect in accordance with the provisions of the agreements evidencing those awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Options
may be granted with respect to a number of shares of Common Stock in excess of the number of shares at the time available for issuance
under the Plan, <U>provided</U> each granted option is not to become exercisable, in whole or in part, at any time prior to stockholder
approval of an amendment authorizing a sufficient increase in the number of shares issuable under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IV.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any cash proceeds received by
the Company from the sale of shares pursuant to options or stock issuances granted under the Plan shall be used for general corporate
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>V.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
REGULATORY APPROVALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The implementation of the Plan, the granting of any option hereunder, and the issuance of stock (i) upon the exercise
or surrender of any option or (ii) under the Stock Issuance Program shall be subject to the procurement by the Company of all approvals
and permits required by regulatory authorities having jurisdiction over the Plan, the options granted under it and the stock issued pursuant
to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
No shares of Common Stock or other assets shall be issued or delivered under the Plan unless and until there
shall have been compliance with all applicable requirements of Federal and state securities laws, including (to the extent required) the
filing and effectiveness of the Form S-8 registration statement for the shares of Common Stock issuable under the Plan, and all applicable
listing requirements of any stock exchange (or the Nasdaq National Market, the Nasdaq Global Select Market or any successor system, if
applicable) on which Common Stock is then trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>VI.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
NO EMPLOYMENT/SERVICE RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Neither the action of the Company
in establishing or restating the Plan, nor any action taken by the Plan Administrator hereunder, nor any provision of the Plan shall be
construed so as to grant any individual the right to remain in the employ or service of the Company (or any parent or subsidiary corporation)
for any period of specific duration, and the Company (or any parent or subsidiary corporation retaining the services of such individual)
may terminate such individual&rsquo;s employment or service at any time and for any reason, with or without cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>VII.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
MISCELLANEOUS PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
to the extent otherwise expressly provided in the Plan, the right to acquire Common Stock or other awards under the Plan may not be assigned,
encumbered or otherwise transferred by any grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Awards issued
under the Plan shall be subject to any clawback policy of the Company as in effect from time-to-time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The provisions of
the Plan relating to the exercise of options and the issuance and/or vesting of shares shall be governed by the laws of the State of Delaware
without resort to that state&rsquo;s conflict-of-laws provisions, as such laws are applied to contracts entered into and performed in
such State.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Plan is intended to be an unfunded plan. Grantees are and shall at all times be general creditors of the Company with respect to their
awards. If the Committee or the Company chooses to set aside funds in a trust or otherwise for the payment of awards under the Plan, such
funds shall at all times be subject to the claims of the creditors of the Company in the event of its bankruptcy or insolvency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Awards
to Non-U.S. Employees</U>. </B>The Committee shall have the power and authority to determine which subsidiary corporations shall be covered
by this Plan and which employees outside the United States shall be eligible to participate in the Plan. The Committee may adopt, amend,
or rescind rules, procedures, or sub-plans relating to the operation and administration of the Plan to accommodate the specific requirements
of local laws, procedures, and practices. Without limiting the generality of the foregoing, the Committee is specifically authorized to
adopt rules, procedures, and sub-plans with provisions that limit or modify rights on death, disability, or retirement or on termination
of employment; available methods of exercise or settlement of an award; payment of income, social insurance contributions and payroll
taxes; the withholding procedures and handling of any stock certificates or other indicia of ownership which vary with local requirements.
The Committee may also adopt rules, procedures or sub-plans applicable to particular subsidiary corporations or locations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">23</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>bcrx-20230613.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qlZs7xRiXgen8uAbXMsOaqI6aOdx5B7mekxt211HTmK/y4pwwFGFy2VcfoWYaoD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:BCRX="http://biocryst.com/20230613" elementFormDefault="qualified" targetNamespace="http://biocryst.com/20230613">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://biocryst.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="bcrx-20230613_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bcrx-20230613_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>bcrx-20230613_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>bcrx-20230613_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biocryst.com/role/Cover" xlink:href="bcrx-20230613.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://biocryst.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140228539262800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 13,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioCryst Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1413174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4505 Emperor Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">859-1302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>f8k_061423_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcrx-20230613.xsd" xlink:type="simple"/>
    <context id="From2023-06-13to2023-06-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2023-06-13</startDate>
            <endDate>2023-06-13</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-06-13to2023-06-13">0000882796</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-06-13to2023-06-13">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-06-13to2023-06-13">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-06-13to2023-06-13">2023-06-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-06-13to2023-06-13">BioCryst Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-06-13to2023-06-13">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-06-13to2023-06-13">000-23186</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-06-13to2023-06-13">62-1413174</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-06-13to2023-06-13">4505 Emperor Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-06-13to2023-06-13">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-06-13to2023-06-13">Durham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-06-13to2023-06-13">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-06-13to2023-06-13">27703</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-06-13to2023-06-13">(919)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-06-13to2023-06-13">859-1302</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-06-13to2023-06-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-06-13to2023-06-13">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-06-13to2023-06-13">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-06-13to2023-06-13">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-06-13to2023-06-13">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-06-13to2023-06-13">BCRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-06-13to2023-06-13">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-06-13to2023-06-13">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M9FM=(F5)]?KA@A=KRCU[L[7_$GQE]HZ:1'P-0MYM%W35\<7[.# RS5]V5]+
MJW-^N.4,ZMU> +^OI31O _O^7/S],?H74$L#!!0    ( %DXSE:?H!OPL0(
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( %DXSE8'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 63C.5L5)
MK4[O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ 63C.5IE<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !9.,Y6;;ITT4\$   *
M$0  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ 63C.5I^@&_"Q @  X@P   T              ( !DPP
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !9.,Y6EXJ[',     3 @  "P
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52P4&      D "0 ^ @  YQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="f8k_061423.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biocryst.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="f8k_061423.htm">f8k_061423.htm</File>
    <File>bcrx-20230613.xsd</File>
    <File>bcrx-20230613_lab.xml</File>
    <File>bcrx-20230613_pre.xml</File>
    <File>exh_101.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f8k_061423.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "f8k_061423.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bcrx-20230613_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcrx-20230613_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bcrx-20230613.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "BCRX",
   "nsuri": "http://biocryst.com/20230613",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "f8k_061423.htm",
      "contextRef": "From2023-06-13to2023-06-13",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://biocryst.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "f8k_061423.htm",
      "contextRef": "From2023-06-13to2023-06-13",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://biocryst.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001171843-23-003914-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-23-003914-xbrl.zip
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MP!@JPG3>.?!U8S>X]],6W[A?[AVL=LO_4$L#!!0    ( %DXSE:PV^C.P5@
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M9)')-3Z8%@']N2J@206J8J4FE6'=/E+C\^B:RV UQGGBIZN#60Q&Q;A@IH=
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M.^I;KR37Y\^F@Z':;JDG\V@:,7@N >KAR[GIKN%)F6B[SE"LZM[*IGE#,;J
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M2?>44W!E"SPJO*)%L/7WO=W=<'=W%QOL>=P7^%<[@^C:%D')K!:.R4K&;0K
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M9[>S?W3\\>BX?SH(3H_[AR?]?8IR_K#_KG_X=G 2# ^Q,_?I\='[#0U\KC9
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MFT.T%'R^-@PS,Y 6>4)M=ACL3K(5#CAVM)QG\!()+AJY:M@'@%1W'I\ON'=
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MX\'^L(]D'L'Q\.V[TTTE+EXM?\='HX[!F .E@4&31&'E?(B,Y4TC!!W:S3Y
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M-UVPZRZ2LX3H;"3X.<6ZSP*5C%@BEGXRV NBLPQ)F9>%AFLE!%<1&HC>$C.
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M5C6Z"7^%/3&Z"/6C0XR2+M ((@172 )EA@%YFRI%^RO#UZ7S"G_')W B6+[
M05V"B)B9V:Y:CX@(M)3XCCU?LKTDL6/<.Y$QQ3RA+Z93<V<:YV!DR/P@/38<
M70"ID]$%2B1>'"(\6LC[XKG'U>%N )B!,(81UDN".9_E8"H2Y*R,9P5#*(ET
M&/^)MSZ/D%A@FA4%9[IYTZDHB+ D>#>C#,>B6!!D,( 1+[BQ#_.6.<P7@M^*
MQ"PZC!04).6A82!@ Y^;#: TBG^72"7%L1P8LT"H >'=1\D<#4M<$Z\:N:%P
MF"QFJMO5#:$(B0A>#T('#L&\?KYK5&W?/>FC>5)A:K?['U\'1_R[@'_64R #
MM\@>+[,W=D/902'VJYC?@#+U3JD9B!ZYIO:W/!E%7:<L?_]SD[,F"F2J1V^:
M3)I\S'25I)YL?[DJ$F$"FR EO*BEJBBDV3S3VY&YTG"1<&J\[I'YL]JC1%7;
MW!^[9D!1 5#!KBWU![1ES%$#%S!K95(9P14^8GN<7:5(/4**>0K[^]P(N6F4
MS. U_[48G]MI<;X>?,-JV!UO.=TF]80Z=!I=N0W%;5@(")UKMI>(N42XHP_H
M:UPNL4I"TME\ ,<8R]#/0NV B=@YALQY># I_$*DTV%CY,1QPK(FR\^CU&).
MA)_$BI_ R'U>6%1KYO?$>DCFH] R3@BQQW3V%;R**807&(P.GT9YCI-#O\+F
MLM*_U6<M>1#NMH>,L=XB]_5L]RGWM=;<U[/=I]S7NA,+)\F7EKS"A^$)[M'^
MX>#HTU-.X5["/?T/@\,#^-\I,A6=OAL$'V%Z-R/#P*:?@CB)-Q.S04W&1H%6
MVSR[DKY87C-/@IER0&=LXL^D^*0Z5IC2Q=E!7K:H+#*L3E;DS:FIQ;!\8>:&
M2'%*9JP4]RKT)V4J8]=>U_"F&=, +2\V#DPK/!PHF,CG$E]MP9AX 7C-3&Y1
M+OR&?L:! O#81\R^ Y'/&B)F#R%F4:M>2L-9?L8H8N[H#>I1]W L9?W_"_YW
M>/H.&S2 HM_0T.Y]LY%Q>5JMA9 ]<KC-!=5HDS6"9;==S'5]OS3$F9L2N%:@
M/7UI;T%Y,BHA5-DG9EJ6.R322+*H==L1X=64\R-\>34OQ7$3<W#?Q)B] 3%U
M0O621 PRS4842R!* Q*IKO<5^D0HA:1QA,?:OADG?B5<3;P/F[._8;V'$[>M
MF!LJ_D:H#?:K*!NK^$+;7\"INVY'U2!H%5+;RVXG5G:@KL2H@7PTOJ?G8#J6
MJZW,!/2KDQUFHX6N$*PMK6^+2%RROGX^\UI3!E.'8G(J-C4K1#WR."D25P59
M]?HHKQ@-EQ#);R0AG<;42SN_9IJT9'([FIX$ZVCJ"^]G>DU80061"+I*QW6<
MQ4PQRN&(T%@*AIQ'20(-9K<4AGC<$5I;]+CJCX0)C[<N.8(["(Z">!<-@^HI
MYCLLOR+<8)'GS?U7N8;&#V6V==H8.H(_Z>Y  E6-(O1R>Z9O& ?$I@7%6EWU
M4^S Z*(2J*IXVKHI99U4[6)5&-.PZ.5W@K[9\$CDCP%:"Z8W2'PCX5V5'MP>
MMB'N1:QOJA?KJ>4U&XYU$+,]FOI!'L%&2.]5-<\:O'DSV#\=?AX$!]AS'=ED
MD5<6O;-5>68;:ZY1*I]*UTW%H.)J'FLR#LOQK(F=:M 8=BCA.!K0*/9\H2PU
M25PDC36L%NQ%#9B% ZO^I"\D@LFFV95/-=+2+JJB-MOK_"L4U8*:,LVF.15T
MCKE U"((L<'>FZ)-EJ%O+?)'$T;1$X4<!7\&2N."4\P<&E94V!KKJ[&Z\"7G
MB6C<9,XZO:R<;6< :]_6]XFM=#3V1T,+ZB3WDUIM>"HR*BSHKL70$F_=\I!1
M9($ZGC6$$4)91$8E)OEH,</E'<46 M5LRF%W=]\6"[;.%HVM("T?5YW^"W8$
M<<FR!3#V=-@DIOR?P[VT$IK;0B]KX6FKKXDD??T:8ED(?N\I!+_>$/S>4PC^
M.R8!6XU7^XFZ+((SE658/>?:9K=UOV4?LJ&3ABLL46K'WL]Y>[]]^CV.<K#[
M<TPT6#H0H1SM=@@Z5N&J&C/*8YFT]'1>4DA M,HEGRGR#B:1-,PA.%K#]7H9
M)5.TR;N=B4&7XQPT!G0<W-GAT85H ?E#*AU(C*L;*GX.B5=M8PS:XV>Q\&SP
M_14F?:)&/PFTTY!XT 8>KNE0C,GF,YB0D"E>/+U2CQQ45 U[9]1IN&[DL"+.
M<ND?+-GSI<V3&XV=AJYC[/VO7ZT]V'/W[_M\"P\V>I_7VENNU6;? O3N400W
MP>1UEL,>HD"?(8-)<95H( Z,C4[R@.QS,TIKIS,W469H7!6M6-C4!YS"*+C%
M:2C.:-?$ IKG(TJU8&$C\C^,<"D6$Z1[8]SA"!1983E'ZC1$S:TA-F/_KK0A
MY:>3 7GJQT?[@\'&=J+LFPX4L'.QNT-A2!=0R_F161>/C::QVJ):(2V1_RV=
M0:PO27V6\& +6 X4@M3X=SL&V;]IV_Z^=WW3.3@>O/WTOG]Z=/Q'T/\(I^$S
MU8!NYF%82>C*!V+7BZ;I8*CJ,]%0E>[&>*4U&VW6$6VP6M*#HC#*&/1N:\Q5
M=PQ9%0_-O3\RHK UN8B"8L'9OUKO,IMJ)#4H:&=FR2I,VI#,9\$,8+K!!%@2
MII7!B?C7(D^*<2(A\TM/N3?8LO(N26DGJM E=48^4? C*3=#AJS(M\,V$*U%
MMH+ IM(.MWV<#^.R&Q4=L""/D1.<IFEQ;AT#YPX1Z"=QUG\EK^UU$X?Q2;:*
M"U<I857$L'5YJR%Z13/958@KS6;M<?9IDDRY =78Q<=29;>^P69@)]N_X,;F
MX!^5/%I/<B(5G4N*/QNL/#[Y_EMV.].DH7FZ''+>^):$;TL>>Q@5X^C?\!\<
M%LS(!\H;A?J[M]/L#+XYH>RL7&!@P0Y&7UP7\$:8S21K5\;4<SYOY;78,X3Y
MP#E>_\E;%DM\]A1+7&\L\=E3+/'[C24JF_6^,7&@=8Z"P8>/[X_^0/#K#R>#
MX\_#_4%P/'S[;F-;=!ZJ.F&'+5#&&+.QFFHK,B]S"6[JQ":B6EG(RUW*Z,\X
M78)/46:I^:4-P#4F"9DPH,P7E+"D7%DFA(Z,D+ 0% ]N 8H-<:H2%V%0"1?S
M<+-"_VVE6/0:0S4"S'45T=:3A"'V.  K3 U2K"S9X1$6(:E"Z*^YOY"*F"F6
MT;K4IGO='@?07#B[K3VC M2H]]?1*&DT1A]@. E?@ RD++=0Y!'&;->O@1]:
M%GV;,.IVO#(&#!9]'IY@L^ -%3MW\9 9,4%>ES*L'3H@_C+'@N?IM454F-/N
M/#TK#DP;AQ:?@YO"5MP*/%Y>PY5XC.U4TA$%6=DG<</1W2C.KNDL"3AL,T[-
MG3W&/D\Z^W?5*'QC^(#:W8+C=89&\5QZ&?IR/"IT>PR*.,)K@1VVC?_=H)78
MO\-*G%:S8(I8BIDVN'U1%;EN2TFJ\26A&= @RPH>T6*0*JV".* DB<0#>#9L
MDI@IEU$+(<8JEU 2TGGAE8Y@/4LGL"?*[6RR3?>K5&J[4ERD?5"<*9@ZS".L
MVR'_@P0);;>QJ2:FCP3?2\/;H)UT<+>=U.V8?#=RDQAR?I2A&*B9+.B3.6'B
MWAKP+*V';4N#I@DFZNEE<*^8@#ZL3$)0N\JA;\1Y=3N2JC7I:<5/Y?/CC"XR
MHOW!=%R,$#V$N>- 29:83DZ>L#?Q&%,/C>&3)AT22O]MOEOSZU7BHUR";EZQ
M]9V-87LIC\<(Z5F4_IDOYN5("'J*; I?KX"\\O%NUL$=6P-\^IW5$)D9V#'N
MT\[)3C"03N1"*X^VTNE%G8W.]KAIJ1IT/(,<W&HV^954))860H9>J^)ZO"_?
MP'1(9S0$;E-\^J>4^K:17%(WBV&R$NDQA1GH9)3,4; J(ZE*DT(@=L2NAIQ\
M#BD5 "=KE""T93'%]:%,WWA!7//LQVSC<2YJJL)RF?#,.#>PZNJ1?8:T+]G8
M<*=8ETI'*8F2@ L&./RJAT+2&J4X^DL5VGC;W90E"2Z/Y93(X_.,8/V^C$@L
MS].(B3<D!4_B#&0+SE+3C) 8LU-"DDFI5M):-"153&JPK:GI=S=&' $U+ S9
MZRYE!D@(I1I@0U/B/+Q7"N0PBV'$XX*IB%PYBT]":?@ 7VE1QM48(+LR:2J'
MY#Y$T(&*4AH$%=*?X#K/L!2(Z*=>T23J6B\W-73Y!?PQ5;DJCC<SJR,6P7*M
M&AOEZ,K"\\G0N()U*RZ2N9R#2SQ"-+>\&[R*,EN?IS<U5F:TK)F_B?W>;'QN
M%M.HS5^G7^,@[KE^M2I!_9O:2]L%[2TNJ4=>_;CE;BUJ"3=[]GSILYI"Y<<P
MX]LF8EF/B+\,GL\)XI)Y4>F_>9?J"+6*D],X:T%R\\(8/)4_=?#4&\]M9^V'
MUT<'?R UP0_O3C^\__W_ U!+ P04    " !9.,Y69QY%+407  "5F   #@
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MYPFZ$1N2C+@@\_ L>V0-I6[/*:U5=.+Q>K ( 8B4,@/C7NLCY=64O-7=?IA
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M+GAS9%!+ 0(4 Q0    ( %DXSE:A3?;=_@H  ("&   5              "
M 5<#  !B8W)X+3(P,C,P-C$S7VQA8BYX;6Q02P$"% ,4    " !9.,Y6&<F/
MNE8'  #55P  %0              @ &(#@  8F-R>"TR,#(S,#8Q,U]P<F4N
M>&UL4$L! A0#%     @ 63C.5K#;Z,[!6   NRL"  L              ( !
M$18  &5X:%\Q,#$N:'1M4$L! A0#%     @ 63C.5F<>12U$%P  E9@   X
M             ( !^VX  &8X:U\P-C$T,C,N:'1M4$L%!@     %  4 .@$
' &N&      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
